3D Medicines Biotechnology Shanghai Co Ltd (1244)

Currency in HKD
8.18
+0.98(+13.61%)
Closed·
1244 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Trading near 52-week High
1244 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.228.30
52 wk Range
1.608.30
Key Statistics
Bid/Ask
8.15 / 8.18
Prev. Close
7.2
Open
7.25
Day's Range
7.22-8.3
52 wk Range
1.6-8.3
Volume
1.78M
Average Volume (3m)
449.96K
1-Year Change
73.08%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1244 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

3D Medicines Biotechnology Shanghai Co Ltd Company Profile

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in Phase II clinical trials G/GEJ and TMB-H advanced cancer, EC, HCC, CRC, NSCLC, microsatellite stable CRC, and dMMR advanced sold tumors. In addition, it provides products which is in development pipeline include 3D189 for multi-indication tumor that has completed Phase I and is in phase III clinical trial for the treatment of acute myeloid leukemia (AML); 3D1001 for the treatment of post-surgical dental pain/cancer pain which is in phase II trial; 3D1002 for cancer pain/osteoarthritis and is in phase II trial; 3D229 (GAS6/AXL) for the treatment of acute myeloid leukemia (AML), kidney cancer, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, and prostate cancer and has completed phase I clinical trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy that is in Phase I clinical trial; 3D011 for advanced malignant solid tumor which is in Phase I clinical trial; and 3D057, 3D059, 3D1015, 3D124, 3D060, and 3D062 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

Employees
191
Market
Hong Kong

Compare 1244 to Peers and Sector

Metrics to compare
1244
Peers
Sector
Relationship
P/E Ratio
−8.8x−16.5x−0.5x
PEG Ratio
−0.150.260.00
Price/Book
2.1x6.1x2.6x
Price / LTM Sales
3.6x16.3x3.3x
Upside (Analyst Target)
-3.9%42.8%
Fair Value Upside
Unlock−10.3%6.5%Unlock

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-0.32 / --
Revenue / Forecast
239.23M / --
EPS Revisions
Last 90 days

1244 Income Statement

FAQ

What Stock Exchange Does 3D Medicines Biotechnology Shanghai Trade On?

3D Medicines Biotechnology Shanghai is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for 3D Medicines Biotechnology Shanghai?

The stock symbol for 3D Medicines Biotechnology Shanghai is "1244."

What Is the 3D Medicines Biotechnology Shanghai Market Cap?

As of today, 3D Medicines Biotechnology Shanghai market cap is 2.00B.

What Is 3D Medicines Biotechnology Shanghai's Earnings Per Share (TTM)?

The 3D Medicines Biotechnology Shanghai EPS (TTM) is -0.75.

From a Technical Analysis Perspective, Is 1244 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has 3D Medicines Biotechnology Shanghai Stock Split?

3D Medicines Biotechnology Shanghai has split 0 times.

How Many Employees Does 3D Medicines Biotechnology Shanghai Have?

3D Medicines Biotechnology Shanghai has 191 employees.

What is the current trading status of 3D Medicines Biotechnology Shanghai (1244)?

As of 06 Aug 2025, 3D Medicines Biotechnology Shanghai (1244) is trading at a price of 8.18, with a previous close of 7.20. The stock has fluctuated within a day range of 7.22 to 8.30, while its 52-week range spans from 1.60 to 8.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.